Phase 3 Depression and Anxiety Trial, Recruiting NCT07196501 Sponsor: Neurocrine Biosciences Condition: Depression and Anxiety
Back to Depression And Anxiety

Phase 3 Depression and Anxiety Trial, Recruiting

NCT07196501
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with depression that keeps coming back (moderate or severe) or long-lasting depression.
  • Your current depression has not improved enough with antidepressant pills you have taken by mouth.
  • You have been taking antidepressant pills for at least 8 weeks and are willing to keep taking the same medication at the same dose throughout the study.
  • Your depression score on a standard rating scale is high enough at both your screening appointment and your first study visit (confirm with trial site).
  • You are willing and able to follow all study rules and attend all required appointments, as agreed by the study doctor.

Who may not be able to join:

  • You have been diagnosed with another mental health condition in the past year that was the main focus of your treatment, rather than depression.
  • The study doctor believes you are at immediate risk of harming yourself or others.
  • Your depression did not improve when you previously received electroconvulsive therapy (ECT), also known as "shock therapy," during your current episode of depression.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Development Lead, Neurocrine Biosciences

Phone: 1-877-641-3461

Australian sites

Neurocrine Clinical Site, Carlton, Victoria
Neurocrine Clinical Site, Melbourne, Victoria
Neurocrine Clinical Site, Parkville, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Neurocrine Biosciences
Registry
ClinicalTrials.gov
Start date
18 August 2025
Est. completion
1 July 2028

Where this trial is recruiting

🇦🇺 Australia 🇧🇬 Bulgaria 🇨🇦 Canada 🇪🇪 Estonia 🇮🇹 Italy 🇵🇱 Poland 🇷🇸 Serbia 🇰🇷 South Korea 🇪🇸 Spain 🇹🇼 Taiwan 🇺🇸 United States

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Time from Randomization to Relapse

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov